Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

ADCs, TKIs, and More Expand Treatment Options in HER2+ Metastatic Breast Cancer

August 16th 2021

Mark D. Pegram, MD, discusses the latest data in HER2-positive metastatic breast cancer.

Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL

August 10th 2021

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera

August 6th 2021

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5th 2021

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Pembrolizumab/Lenvatinib Under Evaluation in Frontline Non–Clear Cell RCC

August 4th 2021

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.

Rini Remarks on Remaining Questions With Pembrolizumab/Axitinib in Frontline Advanced Clear Cell RCC

August 4th 2021

At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer

July 28th 2021

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Borghaei Breaks Down the Impact of Sotorasib in KRAS G12C–Mutant NSCLC and Future Research Directions

July 27th 2021

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

Tisagenlecleucel Demonstrates High Rates of Durable Responses in Relapsed/Refractory Follicular Lymphoma

July 23rd 2021

The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with other available products.

Addition of Bortezomib to Bendamustine/Rituximab Induction Therapy Does Not Significantly Improve PFS in MCL

July 21st 2021

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Adavosertib, With or Without Olaparib, Showed Promising Efficacy in PARP-Resistant Ovarian Cancer

July 20th 2021

Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.

Regorafenib/Nivolumab Elicits Better Responses in pMMR/MSS CRC Without Liver Metastases

July 14th 2021

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Tucatinib Detectable in CSF of HER2+ Metastatic Breast Cancer With Leptomeningeal Disease

July 12th 2021

Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.

Lenvatinib/Pembrolizumab’s Favorable HRQoL Leads to “Standout” Option for Frontline RCC

July 9th 2021

Robert J. Motzer, MD, discusses the efficacy and health-related quality of life benefits of lenvatinib/pembrolizumab in patients with advanced RCC, and projected where the regimen might fit into the treatment paradigm.